HIF1A Knockout HEK293T Cell Line

The choice depends on whether you are studying HIF1A's role as the principal hypoxia-inducible transcription factor in a high-transfection-efficiency mechanistic platform. The Knockout line is the standard tool for asking whether HIF1α is required for hypoxic gene induction — HIF1α is the oxygen-regulated subunit of HIF; under normoxia, prolyl hydroxylases (PHD1/2/3) hydroxylate HIF1α at P402/P564, targeting it for VHL-mediated polyubiquitination and proteasomal degradation; under hypoxia, HIF1α stabilizes and binds HRE to drive expression of glycolytic enzymes, VEGF, EPO, and other hypoxic adaptation genes. Overexpression is useful for studying HIF1α gain-of-function effects. For systematic HIF1α biochemistry, the EDITGENE HIF1A Knockout in HEK293T is a workhorse mechanistic platform — HEK293T's very high transfection efficiency supports structure-function studies. This product complements the parallel HIF1A Knockout in HaCaT (also available); HEK293T is preferred for biochemistry and structure-function studies, HaCaT for skin biology and wound healing research. HIF2α (EPAS1) paralog expression analysis aids interpretation given partial functional overlap. Rescue with wild-type, hydroxylation-resistant (P402A/P564A double mutation = constitutively stable HIF1α), or DNA-binding-deficient HIF1α enables comprehensive structure-function studies. The knockout is critical specificity control for PHD inhibitors (roxadustat, daprodustat, vadadustat).

Primary applications: • Hypoxic response: HIF target gene (VEGFA, GLUT1, GAPDH, LDHA, EPO) expression analysis following hypoxia (1% O2) or DMOG/CoCl2 treatment in HIF1A-null cells. • Structure-function studies: HEK293T's high transfection efficiency supports systematic rescue with wild-type, P402A/P564A (stable), DNA-binding-deficient, and other HIF1α variants. • PHD inhibitor specificity: critical genetic control for roxadustat (FDA-approved for CKD anemia), daprodustat, vadadustat, and emerging PHD inhibitors in renal anemia drug development. • HIF1α/HIF2α dissection: parallel HIF2α (EPAS1) expression and analysis to dissect HIF1α-specific versus HIF2α-shared functions. EDITGENE recommends this HEK293T-based model for biochemical HIF1α research and structure-function studies; the parallel HIF1A Knockout in HaCaT (also available) is preferred for skin biology research.

Yes. HIF1A rescue experiments in HEK293T are well-suited for systematic structure-function research: • Construct design: use a codon-modified HIF1A sequence with a small C-terminal tag (FLAG, HA). HIF1α has N-terminal bHLH-PAS (DNA binding/dimerization), central ODD (oxygen-dependent degradation) with P402/P564 hydroxylation sites, NTAD/CTAD transactivation domains — preserve all elements. • Constitutively stable rescue: P402A/P564A double mutation bypasses PHD-VHL degradation, generating constitutively active HIF1α — invaluable for separating hypoxia-induced from constitutive HIF1α functions. • DNA-binding-deficient rescue: bHLH basic region mutations abolish HRE binding. • Functional readout: rescue should restore hypoxia-induced HIF target gene expression. HEK293T transduces with very high efficiency and supports systematic structure-function rescue experiments.